CARMAT Announces the Certification of Its New Automated Manufacturing Site in Bois-d’Arcy For the Production of up to 800 Units a Year at Full Capacity

PARIS--()--Regulatory News:

CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the certification of its new manufacturing site situated in Bois-d’Arcy, near Paris. In line with the schedule, the recently opened automated site is perfectly aligned with CARMAT’s strategic transformation into an industrial company.

The newly available space will allow the production of up to 800 units per year at full capacity to meet the demands of industrial-pace manufacturing as well as the enrollment ramp up in the ongoing PIVOTAL study. Furthermore, this facility will enable the use of new tools, such as robots, to assemble hybrid membranes on the device and a fully-automated software station to set up the prosthesis parameters. This project has been conducted by a dedicated team with the aim to implement best industrial practices in regards to the organization, processes, and IT systems for maximum efficiency and quality.

Stéphane Piat, Chief Executive Officer of CARMAT, commented: “We are delighted to announce the certification of our new manufacturing site based in Bois-d’Arcy, near Paris, which is a true accomplishment as we have achieved it in less than a year from the start of the building construction. CARMAT will now be able to manufacture products in both Vélizy and Bois-d’Arcy. In line with our strategy, the new automated site will enable CARMAT to become an industrial company with the ability to manufacture up to 800 units a year at full capacity in order to support the demand. Thanks to new processes, we will increase production throughput and more importantly, reinforce the quality of our prostheses to better serve patients across the world.”

●●●

About CARMAT: the world’s most advanced total artificial heart project

A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Airbus Group (Matra Défense), Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue,Truffle Capital, a leading European venture capital firm, ALIAD (Air Liquide’s venture capital investor), CorNovum (an investment holding company held 50-50 by Bpifrance and the French State), the family offices of Pierre Bastid (Babalia) and of Dr. Antonino Ligresti (Santé Holdings S.R.L.), Groupe Therabel as well as the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

●●●

Name: CARMAT
ISIN code: FR0010907956
Ticker: ALCAR

●●●

DISCLAIMER
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward‐looking statements that relate to the Company’s objectives. Such forward‐looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registration document filed with the Autorité des Marchés Financiers under number D.18-0169 on March 22, 2018, as well as changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company’s ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials.

Contacts

CARMAT
Stéphane Piat
Chief Executive Officer
Benoît de la Motte
Chief Financial Officer
Tel.: +33 1 39 45 64 50
contact@carmatsas.com
or
Alize RP
Press Relations
Caroline Carmagnol
Najette Chaib
Tel.: +33 1 44 54 36 66
carmat@alizerp.com
or
NewCap
Investor Relations &
Strategic Communication
Dusan Oresansky
Alexia Faure
Tel.: +33 1 44 71 94 94
carmat@newcap.eu

Contacts

CARMAT
Stéphane Piat
Chief Executive Officer
Benoît de la Motte
Chief Financial Officer
Tel.: +33 1 39 45 64 50
contact@carmatsas.com
or
Alize RP
Press Relations
Caroline Carmagnol
Najette Chaib
Tel.: +33 1 44 54 36 66
carmat@alizerp.com
or
NewCap
Investor Relations &
Strategic Communication
Dusan Oresansky
Alexia Faure
Tel.: +33 1 44 71 94 94
carmat@newcap.eu